TriangleDISEASE & TREATMENT SETTING
Endometrial Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Endometrial Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Endometrial Cancer. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
14 more-specific settings
Jemperli: recurrent Endometrial cancer with DMMR stated without a specific alteration after prior therapy →Keytruda: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy →Lenvima: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy →KEYTRUDA: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy →KEYTRUDA QLEX: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy →KEYTRUDA: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy →Lenvima: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy →IMFINZI: recurrent Endometrial cancer with DMMR stated without a specific alteration →KEYTRUDA QLEX: recurrent Endometrial Carcinoma →Jemperli: recurrent Endometrial cancer →KEYTRUDA: recurrent Endometrial Carcinoma →KEYTRUDA QLEX: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy →Stage I Endometrial Cancer →Stage III recurrent Endometrial Cancer →
Study evidence for this setting
Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
Indication-specific source history
2019-09-17 · Keytruda (pembrolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- event id
- fda-103a2223bc7cad33
- event date
- 2019-09-17
- event kind
- accelerated-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
- match phrase
- endometrial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-8e2ca10938accff47498
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-09-17 · Lenvima (lenvatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- event id
- fda-e029c5040d387a59
- event date
- 2019-09-17
- event kind
- accelerated-approval
- drug or regimen
- Lenvima (lenvatinib)
- source indication text
- In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
- match phrase
- endometrial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-c6b6c214b9ba3eaea663
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-04-22 · Jemperli (dostarlimab-gxly) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- event id
- fda-fcaaccba3db7dec6
- event date
- 2021-04-22
- event kind
- accelerated-approval
- drug or regimen
- Jemperli (dostarlimab-gxly)
- source indication text
- Adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
- match phrase
- endometrial cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f1dd6354fd249eb7e7bd
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-07-21 · Keytruda (pembrolizumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- event id
- fda-30f8c31f47289eb2
- event date
- 2021-07-21
- event kind
- traditional-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
- match phrase
- endometrial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-8e2ca10938accff47498
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-07-21 · Lenvima (lenvatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- event id
- fda-ff89219ab64e6419
- event date
- 2021-07-21
- event kind
- traditional-approval
- drug or regimen
- Lenvima (lenvatinib)
- source indication text
- In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
- match phrase
- endometrial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-c6b6c214b9ba3eaea663
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-02-09 · Jemperli (dostarlimab-gxly) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- event id
- fda-eafead42dcf7ec92
- event date
- 2023-02-09
- event kind
- traditional-approval
- drug or regimen
- Jemperli (dostarlimab-gxly)
- source indication text
- Adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
- match phrase
- endometrial cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f1dd6354fd249eb7e7bd
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- binding id
- ncit-C27815
- source collection
- ncit-concept
- source key
- C27815
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-endometrial-cancer
- binding id
- ncit-C7558
- source collection
- ncit-concept
- source key
- C7558
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice